Skip to main content
Top

20-03-2024 | Bariatric Surgery | REVIEW

Adjuvant and Neo-Adjuvant Anti-Obesity Medications and Bariatric Surgery: A Scoping Review

Authors: Theo Sher, Michelle McGee, Christopher DuCoin, Joseph Sujka, Salvatore Docimo Jr.

Published in: Current Obesity Reports

Login to get access

Abstract

Purpose of Review

To comprehensively summarize the current body of literature on the topic of adjuvant and neoadjuvant pharmacotherapy used in combination with bariatric surgery.

Recent Findings

Anti-obesity medications (AOMs) have been used since the mid-1900s; however, their use in combination with bariatric surgery is a newer area of research that is rapidly growing. Pharmacotherapy may be used before (neoadjuvant) or after (adjuvant) bariatric surgery. Recent literature suggests that adjuvant AOMs may address weight regain and inadequate weight loss following bariatric surgery. Research on neoadjuvant AOM used to optimize weight loss before bariatric surgery is more limited.

Summary

A literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Thirty-four studies were included after screening and exclusion of irrelevant records. Included studies were as follows: seven prospective studies on adjuvant AOM use, 23 retrospective studies on adjuvant AOM use, one prospective study on adjuvant and neoadjuvant AOM use, one retrospective study on adjuvant or neoadjuvant AOM use, one prospective study on neoadjuvant AOM use, and one case series on neoadjuvant AOM use. In the following scoping review, each of these studies is discussed with the goal of presenting a complete synthesis of the current body of literature on AOM use in combination with bariatric surgery.
Literature
1.
go back to reference Stierman B, Afful J, Carroll MD, Chen TC, Davy O, Fink S, Fryar CD, Gu Q, Hales CM, Hughes JP, Ostchega Y, Storandt RJ, Akinbami LJ, National Center for Health Statistics (U.S.). National health and nutrition examination survey 2017–march 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes. Natl Health Stat Report. 2021. https://stacks.cdc.gov/view/cdc/106273. Stierman B, Afful J, Carroll MD, Chen TC, Davy O, Fink S, Fryar CD, Gu Q, Hales CM, Hughes JP, Ostchega Y, Storandt RJ, Akinbami LJ, National Center for Health Statistics (U.S.). National health and nutrition examination survey 2017–march 2020 prepandemic data files development of files and prevalence estimates for selected health outcomes. Natl Health Stat Report. 2021. https://​stacks.​cdc.​gov/​view/​cdc/​106273.
2.
go back to reference Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021;16(3):e0247307. PubMed PMID: 33760880. Pubmed Central PMCID: PMC7990296. Epub 20210324. eng.PubMedPubMedCentralCrossRef Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. PLoS One. 2021;16(3):e0247307. PubMed PMID: 33760880. Pubmed Central PMCID: PMC7990296. Epub 20210324. eng.PubMedPubMedCentralCrossRef
3.
go back to reference Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006;5(11):919–31. PubMed PMID: 17080028. eng.PubMedCrossRef Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006;5(11):919–31. PubMed PMID: 17080028. eng.PubMedCrossRef
4.
go back to reference Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharmacol. 2009;68(6):852–60. PubMed PMID: 20002079. Pubmed Central PMCID: PMC2810796. eng.PubMedPubMedCentralCrossRef Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharmacol. 2009;68(6):852–60. PubMed PMID: 20002079. Pubmed Central PMCID: PMC2810796. eng.PubMedPubMedCentralCrossRef
5.
go back to reference •• Vosburg RW, El Chaar M, El Djouzi S, Docimo S Jr, Choi D, LaMasters T, et al. Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. Surg Obes Relat Dis. 2022;18(9):1109–19. PubMed PMID: 36028428. Epub 20220714. eng. This review summarizes the anti-obesity pharmacotherapy options that available for use in bariatric surgery patients. It is highly relevant to the current review which analyzes publications on the topic of pharmacotherapy use in bariatric surgery patients.PubMedCrossRef •• Vosburg RW, El Chaar M, El Djouzi S, Docimo S Jr, Choi D, LaMasters T, et al. Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. Surg Obes Relat Dis. 2022;18(9):1109–19. PubMed PMID: 36028428. Epub 20220714. eng. This review summarizes the anti-obesity pharmacotherapy options that available for use in bariatric surgery patients. It is highly relevant to the current review which analyzes publications on the topic of pharmacotherapy use in bariatric surgery patients.PubMedCrossRef
6.
go back to reference Farzam K, Patel P. Tirzepatide. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023. Farzam K, Patel P. Tirzepatide. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
7.
go back to reference Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. Jama. 2016;315(22):2424–34. PubMed PMID: 27299618. Pubmed Central PMCID: PMC5617638. eng.PubMedPubMedCentralCrossRef Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. Jama. 2016;315(22):2424–34. PubMed PMID: 27299618. Pubmed Central PMCID: PMC5617638. eng.PubMedPubMedCentralCrossRef
8.
go back to reference Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev. 2023;24(3):e13543. PubMed PMID: 36579723. Epub 20221229. eng.PubMedCrossRef Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev. 2023;24(3):e13543. PubMed PMID: 36579723. Epub 20221229. eng.PubMedCrossRef
9.
go back to reference Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ : British Medical Journal. 2013;347:f5934.PubMedPubMedCentralCrossRef Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ : British Medical Journal. 2013;347:f5934.PubMedPubMedCentralCrossRef
11.
go back to reference King WC, Hinerman AS, Belle SH, Wahed AS, Courcoulas AP. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. Jama. 2018;320(15):1560–9. PubMed PMID: 30326125. Pubmed Central PMCID: PMC6233795. eng.PubMedPubMedCentralCrossRef King WC, Hinerman AS, Belle SH, Wahed AS, Courcoulas AP. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. Jama. 2018;320(15):1560–9. PubMed PMID: 30326125. Pubmed Central PMCID: PMC6233795. eng.PubMedPubMedCentralCrossRef
12.
go back to reference Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93. PubMed PMID: 15616203. eng.PubMedCrossRef Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93. PubMed PMID: 15616203. eng.PubMedCrossRef
13.
go back to reference Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34. PubMed PMID: 23163728. Epub 20130208. eng.PubMedCrossRef Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34. PubMed PMID: 23163728. Epub 20130208. eng.PubMedCrossRef
14.
go back to reference Baig SJ, Priya P, Mahawar KK, Shah S. Weight regain after bariatric surgery-a multicentre study of 9617 patients from indian bariatric surgery outcome reporting group. Obes Surg. 2019;29(5):1583–92. PubMed PMID: 30729366. eng.PubMedCrossRef Baig SJ, Priya P, Mahawar KK, Shah S. Weight regain after bariatric surgery-a multicentre study of 9617 patients from indian bariatric surgery outcome reporting group. Obes Surg. 2019;29(5):1583–92. PubMed PMID: 30729366. eng.PubMedCrossRef
15.
go back to reference Nedelcu M, Khwaja HA, Rogula TG. Weight regain after bariatric surgery-how should it be defined? Surg Obes Relat Dis. 2016;12(5):1129–30. PubMed PMID: 27350180. Epub 20160429. eng.PubMedCrossRef Nedelcu M, Khwaja HA, Rogula TG. Weight regain after bariatric surgery-how should it be defined? Surg Obes Relat Dis. 2016;12(5):1129–30. PubMed PMID: 27350180. Epub 20160429. eng.PubMedCrossRef
16.
go back to reference El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review. Obes Surg. 2021;31(4):1755–66. PubMed PMID: 33555451. Pubmed Central PMCID: PMC8012333. Epub 20210208. eng.PubMedPubMedCentralCrossRef El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review. Obes Surg. 2021;31(4):1755–66. PubMed PMID: 33555451. Pubmed Central PMCID: PMC8012333. Epub 20210208. eng.PubMedPubMedCentralCrossRef
17.
go back to reference Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22(7 Suppl):s176–85. PubMed PMID: 27356115. eng.PubMed Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22(7 Suppl):s176–85. PubMed PMID: 27356115. eng.PubMed
18.
go back to reference •• Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity-trends using a population level national database. Obes Surg. 2021;31(3):1105–12. PubMed PMID: 32986169. Epub 20200928. eng. This is a large study on trends in pharmacotherapy usage in the United States, which is highly relevant background information for the current review.PubMedCrossRef •• Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity-trends using a population level national database. Obes Surg. 2021;31(3):1105–12. PubMed PMID: 32986169. Epub 20200928. eng. This is a large study on trends in pharmacotherapy usage in the United States, which is highly relevant background information for the current review.PubMedCrossRef
19.
go back to reference Mosli MM, Elyas M. Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction? Saudi J Gastroenterol. 2017;23(2):117–22. PubMed PMID: 28361843. Pubmed Central PMCID: PMC5385714. eng.PubMedPubMedCentralCrossRef Mosli MM, Elyas M. Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction? Saudi J Gastroenterol. 2017;23(2):117–22. PubMed PMID: 28361843. Pubmed Central PMCID: PMC5385714. eng.PubMedPubMedCentralCrossRef
20.
go back to reference Badurdeen D, Hoff AC, Barrichello S, Hedjoudje A, Itani MI, Farha J, et al. Efficacy of liraglutide to prevent weight regain after retrieval of an adjustable intra-gastric balloon-a case-matched study. Obes Surg. 2021;31(3):1204–13. PubMed PMID: 33211267. Epub 20201119. eng.PubMedCrossRef Badurdeen D, Hoff AC, Barrichello S, Hedjoudje A, Itani MI, Farha J, et al. Efficacy of liraglutide to prevent weight regain after retrieval of an adjustable intra-gastric balloon-a case-matched study. Obes Surg. 2021;31(3):1204–13. PubMed PMID: 33211267. Epub 20201119. eng.PubMedCrossRef
21.
go back to reference Badurdeen D, Hoff AC, Hedjoudje A, Adam A, Itani MI, Farha J, et al. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc. 2021;93(6):1316–24.e1. PubMed PMID: 33075366. Epub 20201017. eng.PubMedCrossRef Badurdeen D, Hoff AC, Hedjoudje A, Adam A, Itani MI, Farha J, et al. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc. 2021;93(6):1316–24.e1. PubMed PMID: 33075366. Epub 20201017. eng.PubMedCrossRef
22.
go back to reference Mehta A, Shah S, Dawod E, Hajifathalian K, Kumar R, Igel LI, et al. Impact of adjunctive pharmacotherapy with intragastric balloons for the treatment of obesity. Am Surg. 2023;89(4):707–13. PubMed PMID: 34384255. Epub 20210812. eng.PubMedCrossRef Mehta A, Shah S, Dawod E, Hajifathalian K, Kumar R, Igel LI, et al. Impact of adjunctive pharmacotherapy with intragastric balloons for the treatment of obesity. Am Surg. 2023;89(4):707–13. PubMed PMID: 34384255. Epub 20210812. eng.PubMedCrossRef
23.
go back to reference •• Redmond IP, Shukla AP, Aronne LJ. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021;10(2):81–9. PubMed PMID: 33492629. Epub 20210125. eng. Recent review on adjuvant pharmacotherapy used in combination with bariatric surgery. The current study is an update of the literature presented in this review.PubMedCrossRef •• Redmond IP, Shukla AP, Aronne LJ. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021;10(2):81–9. PubMed PMID: 33492629. Epub 20210125. eng. Recent review on adjuvant pharmacotherapy used in combination with bariatric surgery. The current study is an update of the literature presented in this review.PubMedCrossRef
24.
go back to reference •• Lucas E, Simmons O, Tchang B, Aronne L. Pharmacologic management of weight regain following bariatric surgery. Front Endocrinol (Lausanne). 2022;13:1043595. PubMed PMID: 36699042. Pubmed Central PMCID: PMC9868802. Epub 20230109. eng. Recent review on adjuvant pharmacotherapy used in combination with bariatric surgery. The current study is an update of the literature presented in this review.PubMedCrossRef •• Lucas E, Simmons O, Tchang B, Aronne L. Pharmacologic management of weight regain following bariatric surgery. Front Endocrinol (Lausanne). 2022;13:1043595. PubMed PMID: 36699042. Pubmed Central PMCID: PMC9868802. Epub 20230109. eng. Recent review on adjuvant pharmacotherapy used in combination with bariatric surgery. The current study is an update of the literature presented in this review.PubMedCrossRef
26.
go back to reference Miras AD, Pérez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(7):549–59. PubMed PMID: 31174993. Epub 20190604. eng.PubMedCrossRef Miras AD, Pérez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(7):549–59. PubMed PMID: 31174993. Epub 20190604. eng.PubMedCrossRef
27.
go back to reference Colbourne JRM, Fisher OM, Mo S, Rigas GS, Talbot ML. The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery. Langenbecks Arch Surg. 2023;408(1):115. PubMed PMID: 36867261. Pubmed Central PMCID: PMC9984502. Epub 20230303. eng.PubMedPubMedCentralCrossRef Colbourne JRM, Fisher OM, Mo S, Rigas GS, Talbot ML. The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery. Langenbecks Arch Surg. 2023;408(1):115. PubMed PMID: 36867261. Pubmed Central PMCID: PMC9984502. Epub 20230303. eng.PubMedPubMedCentralCrossRef
28.
go back to reference Rye P, Modi R, Cawsey S, Sharma AM. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8. PubMed PMID: 30022424. eng.PubMedCrossRef Rye P, Modi R, Cawsey S, Sharma AM. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8. PubMed PMID: 30022424. eng.PubMedCrossRef
29.
go back to reference Elhag W, El Ansari W, Abdulrazzaq S, Elsherif M, Mustafa I. Lorcaserin vs. Phentermine among non-surgical and surgical obese patients: anthropometric, glycemic, lipid, safety and cost outcomes. Ann Med Surg (Lond). 2019;45:75–81. PubMed PMID: 31388419. Pubmed Central PMCID: PMC6677860. Epub 20190713. eng.PubMedCrossRef Elhag W, El Ansari W, Abdulrazzaq S, Elsherif M, Mustafa I. Lorcaserin vs. Phentermine among non-surgical and surgical obese patients: anthropometric, glycemic, lipid, safety and cost outcomes. Ann Med Surg (Lond). 2019;45:75–81. PubMed PMID: 31388419. Pubmed Central PMCID: PMC6677860. Epub 20190713. eng.PubMedCrossRef
30.
go back to reference Malone M, Alger-Mayer SA, Lindstrom J. Use of Orlistat 60 mg in the management of weight loss before bariatric surgery. Ann Pharmacother. 2012;46(6):779–84. PubMed PMID: 22570428. Epub 20120508. eng.PubMedCrossRef Malone M, Alger-Mayer SA, Lindstrom J. Use of Orlistat 60 mg in the management of weight loss before bariatric surgery. Ann Pharmacother. 2012;46(6):779–84. PubMed PMID: 22570428. Epub 20120508. eng.PubMedCrossRef
31.
go back to reference Sari C, Seip RL, Umashanker D. Case report: off label utilization of topiramate and metformin in patients with BMI ≥50 kg/m(2) prior to bariatric surgery. Front Endocrinol (Lausanne). 2021;12:588016. PubMed PMID: 33716960. Pubmed Central PMCID: PMC7947603. Epub 20210225. eng.PubMedCrossRef Sari C, Seip RL, Umashanker D. Case report: off label utilization of topiramate and metformin in patients with BMI ≥50 kg/m(2) prior to bariatric surgery. Front Endocrinol (Lausanne). 2021;12:588016. PubMed PMID: 33716960. Pubmed Central PMCID: PMC7947603. Epub 20210225. eng.PubMedCrossRef
33.
go back to reference Angelidi AM, Kokkinos A, Sanoudou D, Connelly MA, Alexandrou A, Mingrone G, et al. Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. Metabolism. 2023;138:155346. PubMed PMID: 36375643. Epub 20221112. eng.PubMedCrossRef Angelidi AM, Kokkinos A, Sanoudou D, Connelly MA, Alexandrou A, Mingrone G, et al. Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. Metabolism. 2023;138:155346. PubMed PMID: 36375643. Epub 20221112. eng.PubMedCrossRef
34.
go back to reference Jayaprakash MS, Beavers DP, Miller GD, McNatt S, Fernandez A, Edwards-Hampton SA, et al. Impact on cardiovascular health of using phentermine/topiramate in combination with laparoscopic sleeve gastrectomy in super obesity. J Surg Res. 2023;286:41–8. PubMed PMID: 36753948. Epub 20230206. eng.PubMedCrossRef Jayaprakash MS, Beavers DP, Miller GD, McNatt S, Fernandez A, Edwards-Hampton SA, et al. Impact on cardiovascular health of using phentermine/topiramate in combination with laparoscopic sleeve gastrectomy in super obesity. J Surg Res. 2023;286:41–8. PubMed PMID: 36753948. Epub 20230206. eng.PubMedCrossRef
35.
go back to reference Zoss I, Piec G, Horber FF. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band. Obes Surg. 2002;12(1):113–7. PubMed PMID: 11868286. eng.PubMedCrossRef Zoss I, Piec G, Horber FF. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band. Obes Surg. 2002;12(1):113–7. PubMed PMID: 11868286. eng.PubMedCrossRef
36.
go back to reference Ard JD, Beavers DP, Hale E, Miller G, McNatt S, Fernandez A. Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m(2) or more. Surg Obes Relat Dis. 2019;15(7):1039–43. PubMed PMID: 31147285. Epub 20190419. eng.PubMedCrossRef Ard JD, Beavers DP, Hale E, Miller G, McNatt S, Fernandez A. Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m(2) or more. Surg Obes Relat Dis. 2019;15(7):1039–43. PubMed PMID: 31147285. Epub 20190419. eng.PubMedCrossRef
37.
go back to reference Suliman M, Buckley A, Al Tikriti A, Tan T, le Roux CW, Lessan N, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498–501. PubMed PMID: 30768836. Epub 20190325. eng.PubMedCrossRef Suliman M, Buckley A, Al Tikriti A, Tan T, le Roux CW, Lessan N, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498–501. PubMed PMID: 30768836. Epub 20190325. eng.PubMedCrossRef
38.
go back to reference Thakur U, Bhansali A, Gupta R, Rastogi A. Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, placebo-control study. Obes Surg. 2021;31(1):84–92. PubMed PMID: 32656729. Epub 20200712. eng.PubMedCrossRef Thakur U, Bhansali A, Gupta R, Rastogi A. Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, placebo-control study. Obes Surg. 2021;31(1):84–92. PubMed PMID: 32656729. Epub 20200712. eng.PubMedCrossRef
39.
go back to reference Horber FF, Steffen R. Reversal of long-term weight regain after Roux-en-Y gastric bypass using liraglutide or surgical revision. a prospective study. Obes Surg. 2021;31(1):93–100. PubMed PMID: 32691401. Pubmed Central PMCID: PMC7808975. Epub 20200721. eng.PubMedCrossRef Horber FF, Steffen R. Reversal of long-term weight regain after Roux-en-Y gastric bypass using liraglutide or surgical revision. a prospective study. Obes Surg. 2021;31(1):93–100. PubMed PMID: 32691401. Pubmed Central PMCID: PMC7808975. Epub 20200721. eng.PubMedCrossRef
41.
go back to reference Pajecki D, Halpern A, Cercato C, Mancini M, de Cleva R, Santo MA. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40(3):191–5. PubMed PMID: 23912365. eng.PubMedCrossRef Pajecki D, Halpern A, Cercato C, Mancini M, de Cleva R, Santo MA. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40(3):191–5. PubMed PMID: 23912365. eng.PubMedCrossRef
42.
go back to reference Schwartz J, Chaudhry UI, Suzo A, Durkin N, Wehr AM, Foreman KS, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016;26(2):452–8. PubMed PMID: 26615406. eng.PubMedCrossRef Schwartz J, Chaudhry UI, Suzo A, Durkin N, Wehr AM, Foreman KS, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016;26(2):452–8. PubMed PMID: 26615406. eng.PubMedCrossRef
43.
go back to reference Gorgojo-Martínez JJ, Feo-Ortega G, Serrano-Moreno C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg Obes Relat Dis. 2016;12(10):1856–63. PubMed PMID: 27256860. Epub 20160220. eng.PubMedCrossRef Gorgojo-Martínez JJ, Feo-Ortega G, Serrano-Moreno C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg Obes Relat Dis. 2016;12(10):1856–63. PubMed PMID: 27256860. Epub 20160220. eng.PubMedCrossRef
44.
go back to reference Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500. PubMed PMID: 27986587. Pubmed Central PMCID: PMC6114136. Epub 20161027. eng.PubMedCrossRef Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500. PubMed PMID: 27986587. Pubmed Central PMCID: PMC6114136. Epub 20161027. eng.PubMedCrossRef
45.
go back to reference Hanipah ZN, Nasr EC, Bucak E, Schauer PR, Aminian A, Brethauer SA, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8. PubMed PMID: 29287757. Epub 20171009. eng.CrossRef Hanipah ZN, Nasr EC, Bucak E, Schauer PR, Aminian A, Brethauer SA, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8. PubMed PMID: 29287757. Epub 20171009. eng.CrossRef
46.
go back to reference Srivastava G, Buffington C. A specialized medical management program to address post-operative weight regain in bariatric patients. Obes Surg. 2018;28(8):2241–6. PubMed PMID: 29464536. eng.PubMedCrossRef Srivastava G, Buffington C. A specialized medical management program to address post-operative weight regain in bariatric patients. Obes Surg. 2018;28(8):2241–6. PubMed PMID: 29464536. eng.PubMedCrossRef
47.
go back to reference Stanford FC, Toth AT, Shukla AP, Pratt JS, Cena H, Biino G, et al. Weight loss medications in older adults after bariatric surgery for weight regain or inadequate weight loss: a multicenter study. Bariatr Surg Pract Patient Care. 2018;13(4):171–8. PubMed PMID: 30595995. Pubmed Central PMCID: PMC6306651. Epub 20181210. eng.PubMedPubMedCentralCrossRef Stanford FC, Toth AT, Shukla AP, Pratt JS, Cena H, Biino G, et al. Weight loss medications in older adults after bariatric surgery for weight regain or inadequate weight loss: a multicenter study. Bariatr Surg Pract Patient Care. 2018;13(4):171–8. PubMed PMID: 30595995. Pubmed Central PMCID: PMC6306651. Epub 20181210. eng.PubMedPubMedCentralCrossRef
48.
49.
go back to reference Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen RAG. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):e12323. PubMed PMID: 31183988. Pubmed Central PMCID: PMC6771702. Epub 20190610. eng.PubMedPubMedCentralCrossRef Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen RAG. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):e12323. PubMed PMID: 31183988. Pubmed Central PMCID: PMC6771702. Epub 20190610. eng.PubMedPubMedCentralCrossRef
50.
go back to reference Istfan NW, Anderson WA, Hess DT, Yu L, Carmine B, Apovian CM. The mitigating effect of phentermine and topiramate on weight regain after Roux-en-Y Gastric bypass surgery. Obesity (Silver Spring). 2020;28(6):1023–30. PubMed PMID: 32441476. Pubmed Central PMCID: PMC7250052. eng.PubMedCrossRef Istfan NW, Anderson WA, Hess DT, Yu L, Carmine B, Apovian CM. The mitigating effect of phentermine and topiramate on weight regain after Roux-en-Y Gastric bypass surgery. Obesity (Silver Spring). 2020;28(6):1023–30. PubMed PMID: 32441476. Pubmed Central PMCID: PMC7250052. eng.PubMedCrossRef
51.
go back to reference Edgerton C, Mehta M, Mou D, Dey T, Khaodhiar L, Tavakkoli A. Patterns of weight loss medication utilization and outcomes following bariatric surgery. J Gastrointest Surg. 2021;25(2):369–77. PubMed PMID: 33420652. Epub 20210108. eng.PubMedCrossRef Edgerton C, Mehta M, Mou D, Dey T, Khaodhiar L, Tavakkoli A. Patterns of weight loss medication utilization and outcomes following bariatric surgery. J Gastrointest Surg. 2021;25(2):369–77. PubMed PMID: 33420652. Epub 20210108. eng.PubMedCrossRef
52.
go back to reference Gazda CL, Clark JD, Lingvay I, Almandoz JP. Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes. Obesity (Silver Spring). 2021;29(5):829–36. PubMed PMID: 33818009. Epub 20210404. eng.PubMedCrossRef Gazda CL, Clark JD, Lingvay I, Almandoz JP. Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes. Obesity (Silver Spring). 2021;29(5):829–36. PubMed PMID: 33818009. Epub 20210404. eng.PubMedCrossRef
53.
go back to reference Elhag W, El Ansari W. Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg. 2022;32(4):1005–15. PubMed PMID: 35060021. Epub 20220120. eng.PubMedCrossRef Elhag W, El Ansari W. Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg. 2022;32(4):1005–15. PubMed PMID: 35060021. Epub 20220120. eng.PubMedCrossRef
54.
go back to reference Lautenbach A, Wernecke M, Huber TB, Stoll F, Wagner J, Meyhöfer SM, et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis. Obes Surg. 2022;32(10):3280–8. PubMed PMID: 35879524. Pubmed Central PMCID: PMC9532334. Epub 20220725. eng.PubMedPubMedCentralCrossRef Lautenbach A, Wernecke M, Huber TB, Stoll F, Wagner J, Meyhöfer SM, et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis. Obes Surg. 2022;32(10):3280–8. PubMed PMID: 35879524. Pubmed Central PMCID: PMC9532334. Epub 20220725. eng.PubMedPubMedCentralCrossRef
55.
go back to reference Muratori F, Vignati F, Di Sacco G, Gavazzi L, Pellegrino D, Del Prete M. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. 2022;27(7):2775–81.CrossRef Muratori F, Vignati F, Di Sacco G, Gavazzi L, Pellegrino D, Del Prete M. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. 2022;27(7):2775–81.CrossRef
56.
go back to reference Jensen AB, Renström F, Aczél S, Folie P, Biraima-Steinemann M, Beuschlein F, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017–25. PubMed PMID: 36765019. Pubmed Central PMCID: PMC9918402. Epub 20230211. eng.PubMedPubMedCentralCrossRef Jensen AB, Renström F, Aczél S, Folie P, Biraima-Steinemann M, Beuschlein F, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017–25. PubMed PMID: 36765019. Pubmed Central PMCID: PMC9918402. Epub 20230211. eng.PubMedPubMedCentralCrossRef
57.
go back to reference Lautenbach A, Kantowski T, Wagner J, Mann O, Stoll F, Aberle J. Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure. Clin Obes. 2023;26:e12593. PubMed PMID: 37364260. Epub 20230626. eng.CrossRef Lautenbach A, Kantowski T, Wagner J, Mann O, Stoll F, Aberle J. Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure. Clin Obes. 2023;26:e12593. PubMed PMID: 37364260. Epub 20230626. eng.CrossRef
58.
go back to reference Murvelashvili N, Xie L, Schellinger JN, Mathew MS, Marroquin EM, Lingvay I, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). 2023;31(5):1280–9. PubMed PMID: 36998152. Epub 20230330. eng.PubMedCrossRef Murvelashvili N, Xie L, Schellinger JN, Mathew MS, Marroquin EM, Lingvay I, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). 2023;31(5):1280–9. PubMed PMID: 36998152. Epub 20230330. eng.PubMedCrossRef
59.
go back to reference Wong G, Garner EM, Takkouche S, Spann MD, English WJ, Albaugh VL, et al. Combination anti-obesity medications to effectively treat bariatric surgery weight regain at an academic obesity center. Obes Sci Pract. 2023;9(3):203–9. PubMed PMID: 37287513. Pubmed Central PMCID: PMC10242249. Epub 20220924. eng.PubMedCrossRef Wong G, Garner EM, Takkouche S, Spann MD, English WJ, Albaugh VL, et al. Combination anti-obesity medications to effectively treat bariatric surgery weight regain at an academic obesity center. Obes Sci Pract. 2023;9(3):203–9. PubMed PMID: 37287513. Pubmed Central PMCID: PMC10242249. Epub 20220924. eng.PubMedCrossRef
60.
go back to reference Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163–71. PubMed PMID: 24136928. Epub 20131017. eng.PubMedCrossRef Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163–71. PubMed PMID: 24136928. Epub 20131017. eng.PubMedCrossRef
61.
go back to reference Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discovery. 2022;21(3):201–23.PubMedCrossRef Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discovery. 2022;21(3):201–23.PubMedCrossRef
62.
go back to reference Athanasiadis DI, Martin A, Kapsampelis P, Monfared S, Stefanidis D. Factors associated with weight regain post-bariatric surgery: a systematic review. Surg Endosc. 2021;35(8):4069–84. PubMed PMID: 33650001. Epub 20210301. eng.PubMedCrossRef Athanasiadis DI, Martin A, Kapsampelis P, Monfared S, Stefanidis D. Factors associated with weight regain post-bariatric surgery: a systematic review. Surg Endosc. 2021;35(8):4069–84. PubMed PMID: 33650001. Epub 20210301. eng.PubMedCrossRef
63.
go back to reference Spaniolas K, Bates AT, Docimo S Jr, Obeid NR, Talamini MA, Pryor AD. Single stage conversion from adjustable gastric banding to sleeve gastrectomy or Roux-en-Y gastric bypass: an analysis of 4875 patients. Surg Obes Relat Dis. 2017;13(11):1880–4. PubMed PMID: 28797672. Epub 20170715. eng.PubMedCrossRef Spaniolas K, Bates AT, Docimo S Jr, Obeid NR, Talamini MA, Pryor AD. Single stage conversion from adjustable gastric banding to sleeve gastrectomy or Roux-en-Y gastric bypass: an analysis of 4875 patients. Surg Obes Relat Dis. 2017;13(11):1880–4. PubMed PMID: 28797672. Epub 20170715. eng.PubMedCrossRef
64.
go back to reference Drakos P, Volteas P, Khomutova A, Yang J, Nie L, Pryor AD, et al. The durability of revisional sleeve gastrectomy and Roux-en-Y gastric bypass after previous adjustable gastric band. Surg Endosc. 2023;37(3):2326–34. PubMed PMID: 36220986. Epub 20221011. eng.PubMedCrossRef Drakos P, Volteas P, Khomutova A, Yang J, Nie L, Pryor AD, et al. The durability of revisional sleeve gastrectomy and Roux-en-Y gastric bypass after previous adjustable gastric band. Surg Endosc. 2023;37(3):2326–34. PubMed PMID: 36220986. Epub 20221011. eng.PubMedCrossRef
65.
go back to reference Benotti PN, Still CD, Wood GC, Akmal Y, King H, El Arousy H, et al. Preoperative weight loss before bariatric surgery. Arch Surg. 2009;144(12):1150–5. PubMed PMID: 20026834. Pubmed Central PMCID: PMC4139063. eng.PubMedPubMedCentralCrossRef Benotti PN, Still CD, Wood GC, Akmal Y, King H, El Arousy H, et al. Preoperative weight loss before bariatric surgery. Arch Surg. 2009;144(12):1150–5. PubMed PMID: 20026834. Pubmed Central PMCID: PMC4139063. eng.PubMedPubMedCentralCrossRef
66.
go back to reference Anderin C, Gustafsson UO, Heijbel N, Thorell A. Weight loss before bariatric surgery and postoperative complications: data from the Scandinavian Obesity Registry (SOReg). Ann Surg. 2015;261(5):909–13. PubMed PMID: 25211265. eng.PubMedCrossRef Anderin C, Gustafsson UO, Heijbel N, Thorell A. Weight loss before bariatric surgery and postoperative complications: data from the Scandinavian Obesity Registry (SOReg). Ann Surg. 2015;261(5):909–13. PubMed PMID: 25211265. eng.PubMedCrossRef
67.
go back to reference Samaan JS, Zhao J, Qian E, Hernandez A, Toubat O, Alicuben ET, et al. Preoperative Weight Loss as a Predictor of Bariatric Surgery Postoperative Weight Loss and Complications. J Gastrointest Surg. 2022;26(1):86–93. PubMed PMID: 34145492. Epub 20210618. eng.PubMedCrossRef Samaan JS, Zhao J, Qian E, Hernandez A, Toubat O, Alicuben ET, et al. Preoperative Weight Loss as a Predictor of Bariatric Surgery Postoperative Weight Loss and Complications. J Gastrointest Surg. 2022;26(1):86–93. PubMed PMID: 34145492. Epub 20210618. eng.PubMedCrossRef
68.
go back to reference Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–64. PubMed PMID: 35441470. Pubmed Central PMCID: PMC9542252. Epub 20220519. eng.PubMedPubMedCentralCrossRef Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–64. PubMed PMID: 35441470. Pubmed Central PMCID: PMC9542252. Epub 20220519. eng.PubMedPubMedCentralCrossRef
69.
go back to reference Verrotti A, Parisi P, Agostinelli S, Loiacono G, Marra F, Coppola G, et al. Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study. CNS Drugs. 2015;29(2):163–9. PubMed PMID: 25655110. eng.PubMedCrossRef Verrotti A, Parisi P, Agostinelli S, Loiacono G, Marra F, Coppola G, et al. Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study. CNS Drugs. 2015;29(2):163–9. PubMed PMID: 25655110. eng.PubMedCrossRef
70.
go back to reference Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443–51. PubMed PMID: 23812094. Epub 20130701. eng.PubMedCrossRef Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443–51. PubMed PMID: 23812094. Epub 20130701. eng.PubMedCrossRef
71.
go back to reference Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10(1):14–30. PubMed PMID: 33410104. Pubmed Central PMCID: PMC7787121. Epub 20210106. eng.PubMedPubMedCentralCrossRef Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10(1):14–30. PubMed PMID: 33410104. Pubmed Central PMCID: PMC7787121. Epub 20210106. eng.PubMedPubMedCentralCrossRef
72.
go back to reference Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022;18(12):1345–56. PubMed PMID: 36280539. Epub 20221021. eng.PubMedCrossRef Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022;18(12):1345–56. PubMed PMID: 36280539. Epub 20221021. eng.PubMedCrossRef
Metadata
Title
Adjuvant and Neo-Adjuvant Anti-Obesity Medications and Bariatric Surgery: A Scoping Review
Authors
Theo Sher
Michelle McGee
Christopher DuCoin
Joseph Sujka
Salvatore Docimo Jr.
Publication date
20-03-2024
Publisher
Springer US
Published in
Current Obesity Reports
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-024-00558-z
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.